Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for microvascular-targeted therapies in allograft nephropathy; leaves open clinical translation pending interventional data.
The goals of this presentation are two-fold: (1) to briefly sketch the field of vascular rarefaction as a key component of various fibrotic diseases and (2) to illustrate it with four vignettes depicting diverse mechanisms of microvascular rarefaction. Specifically, I shall describe migratory and angiogenic incompetence of endothelial cells under conditions of reduced bioavailability of nitric oxide, role of endothelial-to-mesenchymal cell and mesenchymal stem cell-to-endothelial reprogramming, and potential role of antiangiogenic peptides in the development of graft vascular disease as exemplified by chronic allograft nephropathy.
No takes yet. Share an insight, caveat, or question.
Michael S. Goligorsky (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: